-- Approval follows positive opinion by European Committee for Medicinal Products for Human Use
-- Approval based on safety and immunogenicity results from three Phase 3 clinical trials
-- Statistically significantly higher and faster rates of protection and similar safety compared to Engerix-B in all 3 trials
-- HEPLISAV B is the only 2-dose adult hepatitis B vaccine offering protection in just 1 month
https://finance.yahoo.com/news/dynavax-announces-european-commission-marketing-172000389.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.